Part 2 of 3 in a Series on Parallel Trade

Building on the legal framework explored in Part 1, this second paper introduces a practical framework to help Marketing Authorization Holders (MAHs) assess the likelihood of parallel trade across their product portfolio.

Central to this framework is the Effort vs. Opportunity Matrix — a structured framework that evaluates how much effort a parallel trader must invest to purchase a product in one EU market, repackage it, and sell it in another, weighed against the financial opportunity this presents.

Four key factors drive this assessment: pricing strategy, geographic scope and launch sequence, artwork and packaging and SKU clustering, and supply chain and distribution channel strategies. Together, these factors help companies identify where parallel trade likelihood is concentrated — both at the individual product level and across their broader portfolio.

For many pharmaceutical companies, particularly those entering the European market for the first time, a fully centralized hub is highly appealing. It offers potential economies of scale, unified oversight, harmonized reporting, and simplified coordination to support early launch activities. However, Europe remains a fragmented landscape of 27 European Union (EU) member states, each with its own laws, pricing regimes, and logistical infrastructures. As an organization matures, achieves sales growth, enters new markets, and faces increasing regulatory complexity, early centralization decisions must often be revisited. This inflection point signals the need for a shift toward localized or hybrid distribution to maintain efficient uninterrupted patient access and compliance.

This white paper is designed for pharmaceutical supply chain leaders seeking to navigate this complexity. It offers a set of guiding dimensions to assess when and how to localize distribution strategies. In the following sections, we will explore the regulatory drivers reshaping the landscape, delve into market and commercial considerations, and provide key strategic questions to help determine when a local approach makes the most strategic sense.

Part 1 of 3 in a Series on Parallel Trade

This first paper in a three-part series explores the legally supported practice of parallel trade in the European Union (EU) pharmaceutical market. Grounded in the EU principle of free movement of goods, it examines the legal framework governing parallel trade, outlines the regulatory requirements that parallel distributors must meet, and explains how Marketing Authorisation Holders (MAHs) can identify parallel trade activity affecting their products. The paper also analyzes why awareness of parallel trade is critical for companies operating in the EU, particularly as MAHs face increasing obligations to ensure appropriate and continued supply while navigating growing drug shortage prevention requirements. These opposing forces create a complex balancing act, requiring MAHs to maintain supply continuity, compliance, and patient access while respecting the legal right to parallel trade.

In a previous white paper, we explored the challenges pharmaceutical companies face in selecting the right European distribution partners and in building sustainable, mutually beneficial partnerships. Now, we shift our focus to the complexity of the European pharmaceutical distribution network, asking a key question: Can a centralized distribution model work in Europe, or do the continent’s market realities, regulations, infrastructure, and specific therapy requirements demand a more tailored approach?

This paper examines the market dynamics and role of third-party logistics (3PL) in Europe, examines six critical centralization considerations, and explores why a hybrid distribution model may offer the optimal balance for pharmaceutical companies operating across Europe.

In the increasingly competitive and innovation-driven biopharma industry, growth is not only a strategic objective for companies, it’s also a necessity. While expanding market share, launching new products and technologies, and acquiring assets through mergers and acquisitions remain key drivers, international expansion offers a powerful route to sustainable long-term growth. Success in new geographies hinges not only on regulatory acceptance and commercial readiness, but also on the effective design and execution of robust supply chain and distribution strategies. This paper explores the critical supply chain and distribution considerations that underpin international expansion, with a particular focus on the Gulf Cooperation Council (GCC) countries.

Interest in rare disease (RD) therapies continues to rise, with many established companies incorporating RD therapies into their portfolios for the first time. This paper:

• Describes the special challenges associated with distributing RD products
• Outlines the key steps and deliverables for developing and implementing supply chains for RD therapies
• Summarizes the pitfalls that biopharma companies must avoid when working to establish reliable supply chains in rare diseases.